Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
University of Cincinnati Celgene Corporation |
---|---|
Information provided by: | University of Cincinnati |
ClinicalTrials.gov Identifier: | NCT00314665 |
This research study is for patients that have been diagnosed with chronic uveitis, a disease that causes inflammation in the eye. Patients are currently being treated with Remicade, Humira, Methotrexate and or similar chemotherapy type drugs to control this inflammation. Despite these medications, patients still have inflammation in their eyes. Patients are being asked to add an additional drug, thalidomide.
Condition | Intervention | Phase |
---|---|---|
Uveitis |
Drug: Thalidomide |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Active Control, Single Group Assignment, Safety/Efficacy Study |
Official Title: | Use of Thalidomide in Chronic Uveitis |
Estimated Enrollment: | 15 |
Study Start Date: | January 2004 |
Study Completion Date: | August 2006 |
Patients will be in the study for approximately 24 weeks. The visits are at screening, baseline (week 0), and weeks 4,8,12, and 24.
The purpose of this research study is to see if Thalidomide is safe and effective in the treatment of patients with chronic inflammation in their eyes.
Thalidomide is approved by the Food and Drug Administration (FDA) for a leprosy skin condition, erythema nodosum leprosum (ENL). The drug works in many different ways, including as an anti-inflammation drug. Therefore, it is thought that this drug might be able to improve symptoms and lung function. At this time, the drug is not approved for use for uveitis.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Despite these medications, you still have inflammation in your eyes. You are being asked to add an additional drug, thalidomide.
Exclusion Criteria:
You will not participate in this research study if any of the following apply to you:
United States, Ohio | |
University of Cincinnati Medical Center | |
Cincinnati, Ohio, United States, 45267-0565 |
Principal Investigator: | Robert P Baughman, MD | Professor of Medicine |
Study ID Numbers: | 03-08-28-05 |
Study First Received: | April 12, 2006 |
Last Updated: | December 3, 2007 |
ClinicalTrials.gov Identifier: | NCT00314665 History of Changes |
Health Authority: | United States: Institutional Review Board; United States: Food and Drug Administration |
Sarcoidosis Chronic Uveitis Uveitis Thalidomide |
Anti-Bacterial Agents Immunologic Factors Thalidomide Uveitis |
Eye Diseases Sarcoidosis Angiogenesis Inhibitors Immunosuppressive Agents |
Anti-Infective Agents Uveal Diseases Thalidomide Immunologic Factors Antineoplastic Agents Growth Substances Eye Diseases Physiological Effects of Drugs Immunosuppressive Agents |
Angiogenesis Inhibitors Pharmacologic Actions Anti-Bacterial Agents Uveitis Therapeutic Uses Growth Inhibitors Angiogenesis Modulating Agents Leprostatic Agents |